Henry Schein, Inc. (NASDAQ:HSIC) Receives $87.64 Average Price Target from Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has earned a consensus recommendation of “Hold” from the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $87.6429.

A number of brokerages have recently weighed in on HSIC. Citigroup initiated coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price on the stock. UBS Group reissued a “neutral” rating and issued a $85.00 price target (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a report on Wednesday, May 6th. Mizuho cut their price objective on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Wall Street Zen downgraded Henry Schein from a “buy” rating to a “hold” rating in a report on Sunday, July 12th.

Insider Buying and Selling at Henry Schein

In other news, Director William K. Daniel purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares of the company’s stock, valued at $1,383,800. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.89% of the stock is owned by corporate insiders.

Institutional Trading of Henry Schein

A number of hedge funds have recently modified their holdings of the business. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the 2nd quarter worth about $25,000. MUFG Securities EMEA plc purchased a new stake in Henry Schein in the second quarter worth about $27,000. Flagship Harbor Advisors LLC bought a new position in shares of Henry Schein during the fourth quarter valued at approximately $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein during the fourth quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Henry Schein during the fourth quarter valued at approximately $37,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $87.82 on Wednesday. The business has a 50 day moving average of $79.50 and a 200 day moving average of $77.72. Henry Schein has a 52 week low of $61.94 and a 52 week high of $89.34. The company has a market cap of $10.00 billion, a PE ratio of 26.53, a P/E/G ratio of 1.70 and a beta of 0.81. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts forecast that Henry Schein will post 5.32 earnings per share for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.